בשל "הגנת זכויות יוצרים" מובא להלן קישור לתקציר המאמר. לקריאתו בטקסט מלא, אנא פנה/י לספרייה הרפואית הזמינה לך. 

on: Pediatric patients, especially neonates and infants, are more susceptible to adverse drug events as compared to adults.

In particular, immature small molecule drug metabolism and excretion can result in higher incidences of pediatric toxicity than adults if the pediatric dose is not adjusted.

Area covered: We reviewed the top 29 small molecule drugs prescribed in neonatal and pediatric intensive care units and compiled the mechanisms of their metabolism and excretion.

The ontogeny of Phase I and II drug metabolizing enzymes and transporters (DMETs), particularly relevant to these drugs, are summarized.

The potential effects of DMET ontogeny on the metabolism and excretion of the top pediatric drugs were predicted.

The current regulatory requirements and recommendations regarding safe and effective use of drugs in children are discussed.

A few representative examples of the use of ontogeny-informed physiologically based pharmacokinetic (PBPK) models are highlighted.